MedTrace Logo

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

NCT02343172 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2020-12-09

No results posted yet for this study

Summary

To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the combination is safe and has beneficial effects in patients with liposarcoma.

Conditions

  • Liposarcoma

Interventions

DRUG

HDM201

DRUG

LEE011

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-13
Primary Completion
2019-10-16
Completion
2019-10-16
FDA Drug
Yes

Countries

  • Canada
  • France
  • Germany
  • Singapore
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02343172 on ClinicalTrials.gov